This antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new treatments in an era of rising antibiotic resistance.

B. Riley kept a Buy rating on Universal Technical (UTI) with a $31 price target following a transfer of coverage. The firm is “broadly ...